GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Tucatinib - TUKYSA tablets

Local official-label summaryBase record retrieved 2026-09-09See the evidence for this drug2 sources available - open source summaries, references and comparisons

TUKYSA / tucatinib

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Creatinine transport effects do not rule out acute kidney injury

An isolated creatinine rise can reflect transport effects, but diarrhea-related volume depletion can also cause true injury. The combination-specific severe-renal restriction remains.

Before applying: Assess the clinical course and alternative filtration markers where appropriate; reconcile companion-drug labels.

Evidence for this qualification

Source-specific qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Pfizer Medical / TUKYSA prescribing information

Product / population
TUKYSA tablets for the product-specific HER2-positive breast and colorectal cancer combinations. Companion-drug and indication restrictions remain separate.
Renal measure
Cockcroft-Gault CrCl, mL/min; alternative filtration markers when appropriate

Manufacturer-hosted prescribing information; no DailyMed Set ID or SPL archive check performed for this source.

The combination restriction is retained as printed; companion capecitabine current-label reconciliation remains required.

Renal dosing, restrictions and evidence limits

No tucatinib adjustment is recommended at CrCl 30-89 mL/min. The trastuzumab/capecitabine combination is not recommended at Cockcroft-Gault CrCl <30 mL/min in this source. Severe-impairment pharmacokinetics are unknown; this does not supply an alternative severe-renal regimen.

Tucatinib can raise serum creatinine through tubular transport effects without lowering filtration. Consider alternative renal-function markers for a persistent isolated rise. This is not permission to dismiss kidney injury: severe diarrhea can cause dehydration, hypotension and acute kidney injury. Assess the clinical course and the exact companion-drug labels.

Source revision: 1/2023 | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://www.pfizermedical.com/tukysa

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Pfizer Medical / TUKYSA prescribing information

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

TUKYSA tablets for the product-specific HER2-positive breast and colorectal cancer combinations. Companion-drug and indication restrictions remain separate.

Renal method: Cockcroft-Gault CrCl, mL/min; alternative filtration markers when appropriate
Retrieved: 2026-09-09

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - TUKYSA

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

TUKYSA tablets for the product-specific HER2-positive breast and colorectal cancer combinations. Companion-drug and indication restrictions remain separate.

Renal method: Cockcroft-Gault CrCl, mL/min; creatinine transport can complicate interpretation
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Creatinine transport effects do not rule out acute kidney injury

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

renal measure and combination

Creatinine transport effects do not rule out acute kidney injury

An isolated creatinine rise can reflect transport effects, but diarrhea-related volume depletion can also cause true injury. The combination-specific severe-renal restriction remains.

How to use this: Assess the clinical course and alternative filtration markers where appropriate; reconcile companion-drug labels.

GlobalRPh RX List - TUKYSAPfizer Medical / TUKYSA prescribing information

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopePfizer Medical / TUKYSA prescribing informationGlobalRPh RX List - TUKYSA
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/tukysa-drug/

Exact product and population

TUKYSA tablets for the product-specific HER2-positive breast and colorectal cancer combinations. Companion-drug and indication restrictions remain separate.

RDM54-SCOPE-tucatinib-tukysa · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Pfizer Medical / TUKYSA prescribing information

Open original reference

Open / share this exact local source

Pfizer Medical / product prescribing information · TUKYSA tablets for the product-specific HER2-positive breast and colorectal cancer combinations. Companion-drug and indication restrictions remain separate.

Renal method: Cockcroft-Gault CrCl, mL/min; alternative filtration markers when appropriate
Source date: 1/2023
Retrieved: 2026-09-09

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

No tucatinib adjustment is recommended at CrCl 30-89 mL/min. The trastuzumab/capecitabine combination is not recommended at Cockcroft-Gault CrCl <30 mL/min in this source. Severe-impairment pharmacokinetics are unknown; this does not supply an alternative severe-renal regimen.

Tucatinib can raise serum creatinine through tubular transport effects without lowering filtration. Consider alternative renal-function markers for a persistent isolated rise. This is not permission to dismiss kidney injury: severe diarrhea can cause dehydration, hypotension and acute kidney injury. Assess the clinical course and the exact companion-drug labels.

RDM54-official-tucatinib-tukysa-e94ac64e80-C1 · Source locator: Sections 5.1, 6.1 increased creatinine, 8.6 and 12.3

Source-specific limits

Manufacturer-hosted prescribing information; no DailyMed Set ID or SPL archive check performed for this source.

The combination restriction is retained as printed; companion capecitabine current-label reconciliation remains required.

Source identity and provenance
Source family
product_label
Source
https://www.pfizermedical.com/tukysa
Retrieved
2026-09-09
Exact label title
TUKYSA (tucatinib) tablets
Label revision
1/2023
Renal-function method
Cockcroft-Gault CrCl, mL/min; alternative filtration markers when appropriate
Source date/version
1/2023
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
7f88b1a750b91f9644d73e743c1e183e2133b347e5483f3ba97bc6d64be3bc14
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - TUKYSA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · TUKYSA tablets for the product-specific HER2-positive breast and colorectal cancer combinations. Companion-drug and indication restrictions remain separate.

Renal method: Cockcroft-Gault CrCl, mL/min; creatinine transport can complicate interpretation
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

No tucatinib adjustment is recommended at CrCl 30-89 mL/min. The trastuzumab/capecitabine combination is not recommended at Cockcroft-Gault CrCl <30 mL/min in this source. Severe-impairment pharmacokinetics are unknown; this does not supply an alternative severe-renal regimen.

Tucatinib can raise serum creatinine through tubular transport effects without lowering filtration. Consider alternative renal-function markers for a persistent isolated rise. This is not permission to dismiss kidney injury: severe diarrhea can cause dehydration, hypotension and acute kidney injury. Assess the clinical course and the exact companion-drug labels.

RDM54-rxlist-tucatinib-tukysa-523f9bea94-C1 · Source locator: Dosage and Administration; Renal Impairment; selected Warnings and Precautions

Source-specific limits

Selected sections only. Source mirror and underlying label are not independent confirmations.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/tukysa-drug/
Retrieved
2026-09-09
Renal-function method
Cockcroft-Gault CrCl, mL/min; creatinine transport can complicate interpretation
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
7f88b1a750b91f9644d73e743c1e183e2133b347e5483f3ba97bc6d64be3bc14

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/tukysa-drug/
Source retrieval
2026-09-09. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
a6fa9a58ac1c166b78b3c0a62dbbcb7729538e6a512de815a04e66cb6161d81c
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report